NO20050347L - Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet - Google Patents

Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet

Info

Publication number
NO20050347L
NO20050347L NO20050347A NO20050347A NO20050347L NO 20050347 L NO20050347 L NO 20050347L NO 20050347 A NO20050347 A NO 20050347A NO 20050347 A NO20050347 A NO 20050347A NO 20050347 L NO20050347 L NO 20050347L
Authority
NO
Norway
Prior art keywords
liquid drugs
oral pharmaceutical
pharmaceutical form
improved bioavailability
solid
Prior art date
Application number
NO20050347A
Other languages
English (en)
Inventor
Piero Del Soldato
Giancarlo Santus
Christina Macelloni
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of NO20050347L publication Critical patent/NO20050347L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Farmasøytiske preparater for administtasjon av flytende legemidler i fast oral form, omfattende én eller flere aktive ingredienser, ett eller flere overflateaktive midler og eventuelt en kosurfaktant og/eller en absorpsjonsforsterker, absorbert i en fast, inert bærer.
NO20050347A 2002-06-25 2005-01-21 Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet NO20050347L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
PCT/EP2003/006496 WO2004000273A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability

Publications (1)

Publication Number Publication Date
NO20050347L true NO20050347L (no) 2005-01-21

Family

ID=11450079

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050347A NO20050347L (no) 2002-06-25 2005-01-21 Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet

Country Status (23)

Country Link
US (1) US20060171969A1 (no)
EP (1) EP1526839B1 (no)
JP (1) JP2005530835A (no)
KR (1) KR20060076136A (no)
CN (1) CN1319518C (no)
AT (1) ATE356612T1 (no)
AU (1) AU2003246564B2 (no)
CA (1) CA2491152A1 (no)
DE (1) DE60312523T2 (no)
DK (1) DK1526839T3 (no)
ES (1) ES2285182T3 (no)
HK (1) HK1080364B (no)
IL (1) IL165601A0 (no)
IT (1) ITMI20021392A1 (no)
MX (1) MXPA04012852A (no)
NO (1) NO20050347L (no)
NZ (1) NZ537204A (no)
PL (1) PL206599B1 (no)
PT (1) PT1526839E (no)
RU (1) RU2323003C2 (no)
SI (1) SI1526839T1 (no)
WO (1) WO2004000273A1 (no)
ZA (1) ZA200410109B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030148818A1 (en) * 2002-01-18 2003-08-07 Myrhum Mark C. Golf club woods with wood club head having a selectable center of gravity and a selectable shaft
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7163958B2 (en) 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
JP2008531045A (ja) * 2005-03-04 2008-08-14 ディーエスエム アイピー アセッツ ビー．ブイ． 食品用微粒子状脂質組成物
BRPI0616076A2 (pt) * 2005-09-16 2011-06-07 Dsm Ip Assets Bv composição farmacêutica de lipìdio particulada
WO2007060112A1 (en) 2005-11-23 2007-05-31 Nicox S.A. Salicylic acid derivatives
DK1978947T3 (da) * 2006-02-03 2014-11-03 Nicox Science Ireland Nitrooxyderivater til anvendelse ved behandling af muskeldystrofier
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
WO2009149053A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
RU2673239C2 (ru) 2013-03-13 2018-11-23 Трис Фарма, Инк. Твердые таблетки и капсулы модифицированного высвобождения бензонатата
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
JP2023504756A (ja) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド カンナビノイドを含む口腔用製品
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
CA3160271A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Nanoemulsion for oral use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5266615A (en) * 1975-11-29 1977-06-02 Sawai Seiyaku Kk Manufacturing of solidified oily liquid substance
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
JPS58213073A (ja) * 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
ATE462417T1 (de) * 1998-08-13 2010-04-15 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
AU1881600A (en) * 1998-12-23 2000-07-31 Alza Corporation Dosage forms comprising porous particles
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition

Also Published As

Publication number Publication date
RU2004138554A (ru) 2005-08-27
PL374388A1 (en) 2005-10-17
NZ537204A (en) 2006-07-28
KR20060076136A (ko) 2006-07-04
WO2004000273A1 (en) 2003-12-31
ZA200410109B (en) 2005-09-02
ES2285182T3 (es) 2007-11-16
PT1526839E (pt) 2007-06-06
DE60312523T2 (de) 2008-01-10
CA2491152A1 (en) 2003-12-31
EP1526839B1 (en) 2007-03-14
ATE356612T1 (de) 2007-04-15
AU2003246564B2 (en) 2008-06-12
JP2005530835A (ja) 2005-10-13
EP1526839A1 (en) 2005-05-04
SI1526839T1 (sl) 2007-08-31
US20060171969A1 (en) 2006-08-03
AU2003246564A1 (en) 2004-01-06
PL206599B1 (pl) 2010-08-31
ITMI20021392A1 (it) 2003-12-29
ITMI20021392A0 (it) 2002-06-25
CN1665486A (zh) 2005-09-07
HK1080364B (zh) 2008-02-01
HK1080364A1 (en) 2006-04-28
DK1526839T3 (da) 2007-05-21
RU2323003C2 (ru) 2008-04-27
IL165601A0 (en) 2006-01-15
DE60312523D1 (de) 2007-04-26
CN1319518C (zh) 2007-06-06
MXPA04012852A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
NO20050347L (no) Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet
SE0003449D0 (sv) Anticancer compositions
EA200401252A1 (ru) Микрочастицы лекарственных веществ
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DE60024491D1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
AR018829A1 (es) Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
HK1096034A1 (en) A solid dosage form comprising a fibrate
ATE292453T1 (de) Antivirale arznei
DK1207756T3 (da) Anvendelse af spinosad eller en formulering, der omfatter spinosad
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
CY1107349T1 (el) Αλφα-κετογλουταρικα ενεργα συστατικα και σκευασματα που τα περιεχουν
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
WO2005007070A3 (en) Stable pharmaceutical composition
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
WO2003105826A3 (en) STABLE AND SOLUBLE PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF HIV PROTEASE INHIBITORS AND METHOD FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE DELIVERY OF HIV PROTEASE INHIBITORS
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application